Errata (DOI:10.1016/S1470-2045(07)70203-6);Gemcitabine-associated thrombotic thrombocytopenic purpura

Lancet Oncology

Volumn 8, Issue 7, 2007, Pages 634-641

  Zupancic, Melanie ^a   Shah, Prabodh C ^a   Shah Khan, Farheen ^a   Nagendra, S ^b  

^a Section of Colorectal Surgery   (United States)

^b MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLOROZOTOCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IMMUNOGLOBULIN; INTERLEUKIN 6; LOMUSTINE; MEDROXYPROGESTERONE; METHOTREXATE; MITOMYCIN; MITOMYCIN C; OXALIPLATIN; PREDNISONE; STEROID; TAMOXIFEN; TEGAFUR; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ZINOSTATIN;

ADULT RESPIRATORY DISTRESS SYNDROME; BILE DUCT CARCINOMA; BRAIN HEMORRHAGE; BREAST ADENOCARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CONFUSION; DIALYSIS; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG COMPETITION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPNEA; ENDOTHELIUM INJURY; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOADSORPTION; INCIDENCE; KIDNEY FAILURE; LIVER CELL CARCINOMA; LUNG DISEASE; LUNG EDEMA; LUNG NON SMALL CELL CANCER; NEUROLOGIC DISEASE; NONHUMAN; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEIZURE; SPLENECTOMY; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; VISUAL DISORDER;

EID: 34347209038     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70256-5     Document Type: Erratum

References (45)

1. Murrin R., and Murray J. Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev 20 (2006) 51-60
2. Snyder H., Mittelman A., Oral A., et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer 71 (1993) 1882-1892
3. Cantrell J., Phillips T., and Schein P. Carcinoma-associated hemolytic uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 3 (1985) 723-734
4. Lesesne J., Rothschild N., Erickson B., et al. Cancer-associated haemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 7 (1989) 781-789
5. Nagaya S., Wada H., Oka K., et al. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. Am J Hematol 50 (1995) 237-243
6. Sheldon R., and Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 58 (1986) 1428-1436
7. Porta C., Danova M., Riccardi A., Bobbio-Pallavicini E., and Ascari E. Cancer chemotherapy-related thrombotic thrombocytopenic purpura: biological evidence of increased nitric oxide production. Mayo Clin Proc 74 (1999) 570-574
8. Watson P., Guthrie T., and Caruana R. Cisplatin-associated haemolytic-uremic syndrome. Successful treatment with a staphylococcal protein A column. Cancer 64 (1989) 1400-1403
9. Walker R., Rosenblum M., Kempin S., and Christian M. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer 64 (1989) 1017-1020
10. Alberts S., Townley P., Goldberg R., et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study. Ann Oncol 14 (2003) 580-585
11. Harrell R., Sibley R., and Vogelzang N. Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin. Am J Med 73 (1982) 429-433
12. Montes A., Powles T., O'Brien M., Ashley S., Luckit J., and Treleaven J. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 29A (1993) 1854-1857
13. Kressel B., Ryan K., Duong A., Berenberg J., and Schein P. Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma. Cancer 48 (1981) 1738-1745
14. George J., Vesely S., and Terrell D. The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 41 (2004) 60-67
15. Fujita H., Takemura S., Hyo R., et al. Pulmonary embolism and thrombotic thrombocytopenic purpura in acute promyelocytic leukemia treated with all-trans retinoic acid. Leuk Lymphoma 44 (2003) 1627-1629
16. Sakai C., Takagi T., Wakatsuki S., and Matsuzaki O. Hemolytic-uremic syndrome due to deoxycoformycin: a report of the second case. Intern Med 34 (1995) 593-596
17. Byrnes J., Baquerizo H., Gonzales M., and Hensely G. Thrombotic thrombocytopenic purpura subsequent to acute myelogenous leukemia chemotherapy. Am J Hematol 21 (1986) 299-304
18. Humphreys B., Sharman J., Hendeson J., et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 100 (2004) 2664-2670
19. Fung M., Storniolo A., Nguyen B., Arning M., Brookfield W., and Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85 (1999) 2023-2032
20. Lewin S., Mutch D., Whitcomb B., Liapis H., and Herzog T. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 97 (2005) 228-233
21. Muller S., Schutt P., Bojko P., et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 84 (2005) 110-114
22. Ruiz I., Del Valle J., and Gomez A. Gemcitabine and haemolytic-uraemic syndrome. Ann Oncol 15 (2004) 1575-1576
23. Citarrella P., Gebbia V., Teresi M., et al. Hemolytic uremic syndrome after chemotherapy with gemcitabine and taxotere: a case report. Anticancer Res 22 (2002) 1183-1185
24. Walter R., Joerger M., and Pestalozzi B. Gemcitabine-associated hemolytic-uremic syndrome. Am J Kidney Dis 40 (2002) E16
25. Saif M., and McGee P. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP 6 (2005) 369-374
26. Flombaum C., Mouradian J., Casper E., Erlandson R., and Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis 33 (1999) 555-562
27. Murgo A. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 24 (1987) 161-177
28. Doll D., List A., Greco F., Hainsworth J., Hande K., and Johnson D. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med 105 (1986) 48-51
29. Burkhardt A., Holtje W., and Gebbens J. Vascular lesions following perfusion with bleomycin. Electron-microscopic observations. Virchows Arch A Pathol Anat Histol 372 (1976) 227-236
30. Duperray A., Tranqui L., Alix J., and Cordonnier D. Effect of mitomycin C on prostacyclin synthesis by human endothelial cells. Biochem Pharmacol 37 (1988) 4753-4757
31. Licciardello J., Moake J., Rudy C., Karp D., and Hong W. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 42 (1985) 296-300
32. Cattell V. Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat. Am J Pathol 121 (1985) 88-95
33. Rogers J., Murgo A., Fontana J., and Raich P. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6 (1988) 276-281
34. Veyradier A., Obert B., Houllier A., Meyer D., and Gima J. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98 (2001) 1765-1772
35. Lichtman M., Beutler E., Kipps T., Seligsohn U., Kaushansky K., and Prchal J. Williams Hematology. 7th edn. (2005), McGraw-Hill Companies, Ohio, USA
36. Vesely S., George J., Lammie B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102 (2003) 60-68
37. Serke S., Riess H., Oettle H., and Huhn D. Elevated reticulocyte count-a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. Br J Cancer 79 (1999) 1519-1521
38. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339 (1998) 1578-1584
39. Lammle B., Kremmer Hovinga J., and Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 3 (2005) 1663-1675
40. Hovinga J., Studt J., Alberio L., and Lammle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 41 (2004) 75-82
41. Moake J. Thrombotic microangiopathies. N Eng J Med 347 (2002) 589-600
42. Oleksowicz L., Bhagwati N., and DeLeon-Fernandez M. Deficient activity of von Willebrand's factor cleaving protease in patients with disseminated malignancies. Cancer Res 59 (1999) 2244-2250
43. Nolasco L., Turner N., Bernardo A., et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 106 (2005) 4199-4209
44. Lohrmann H., Adam W., Heymer B., and Kubanek B. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 79 (1973) 368-375
45. Howard M., Williams L., Terrell D., Duvall D., Vesely S., and George J. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 46 (2006) 154-156